Beyond the Promise: Underreported Adverse Effects of Nanomaterials in Human Health Applications

Beyond the Promise: Underreported Adverse Effects of Nanomaterials in Human Health Applications

The burgeoning field of nanomedicine has captivated scientific imagination with its transformative potential across diagnostics, therapeutics, and regenerative medicine ^{3,5,16,23,31,33}. Nanomaterials, engineered at the atomic and molecular scale, offer unprecedented opportunities to interact with biological systems with exquisite precision, promising targeted drug delivery, advanced imaging, and novel biomaterials for tissue repair ^5,6,14,28,53. However, the very properties that confer their therapeutic promise—their diminutive size, high surface area-to-volume ratio, and unique quantum phenomena—also introduce a distinct and complex set of challenges for biological safety assessment ^1,2,6,20. While research has extensively focused on elucidating the beneficial applications, a critical and often underreported dimension pertains to the adverse effects of these nanomaterials on human health. The enthusiasm for innovation must be tempered by rigorous and transparent investigation into potential toxicities, particularly those subtle, chronic, or latent effects that may not be immediately apparent in conventional preclinical or early-phase clinical studies.

This review posits that the adverse effects of nanomaterials in human health applications are systematically underreported, contributing to an incomplete understanding of their true risk-benefit profiles. This phenomenon mirrors broader challenges in scientific and clinical reporting, where negative findings or subtle adverse events are often marginalized or omitted from publications ^9,25,26,43. The unique physicochemical properties of nanomaterials necessitate a paradigm shift in toxicological assessment, moving beyond traditional dose-response models to embrace a more nuanced understanding of nano-bio interactions ^1,2,6,20. We will critically examine the physicochemical determinants governing nanotoxicity, delineate the systemic and organ-specific manifestations of adverse effects, and delve into the complex realm of immunomodulation and chronic inflammation induced by nanomaterials. Furthermore, this review will scrutinize the methodological gaps in current nanotoxicology research and highlight the ethical imperatives for comprehensive and transparent reporting, advocating for a future where the promise of nanomedicine is realized through a foundation of uncompromised safety and accountability.

Contextual Introduction: The Dual Edges of Nanomedicine – Innovation and Unseen Risks

The advent of nanotechnology has ushered in an era of unprecedented scientific and technological advancement, particularly within the biomedical sector. Nanomaterials, defined as materials with at least one dimension in the 1 to 100 nanometer range, exhibit unique physical, chemical, and biological properties distinct from their bulk counterparts ¹¹. These attributes have positioned them as foundational elements for next-generation medical interventions. In diagnostics, nanomaterials are revolutionizing imaging techniques, enabling earlier disease detection and more precise monitoring through enhanced contrast agents and biosensors ³. For therapeutic applications, they offer sophisticated platforms for targeted drug delivery, overcoming biological barriers, improving drug solubility, and reducing systemic toxicity by concentrating active pharmaceutical ingredients at disease sites ^16,31. Beyond drug delivery, nanomaterials are integral to innovative strategies in gene therapy, immunotherapy, and vaccine development ²⁸. In regenerative medicine, they serve as scaffolds for tissue engineering, promoting cellular growth and differentiation, and facilitating the repair of damaged tissues and organs ^33,53. The sheer breadth of these applications underscores the profound promise of nanomedicine to address pressing global health challenges ^5,6,14,23.

However, the very features that confer these remarkable advantages simultaneously introduce complexities in assessing their biological impact. The traditional toxicological paradigm, largely developed for soluble chemical agents, often falls short when confronted with nanomaterials ^1,2,6,20. Unlike molecular drugs, nanomaterials are not simple chemical entities; their toxicity is intricately linked to a constellation of physicochemical properties including size, shape, surface charge, surface chemistry, composition, aggregation state, and dissolution kinetics ^1,2,6,20. These characteristics dictate how nanomaterials interact with biological systems at the cellular, tissue, and systemic levels, influencing their biodistribution, cellular uptake, metabolism, and excretion. For instance, the high surface area-to-volume ratio of nanoparticles allows for extensive interactions with biomolecules, potentially leading to unforeseen biological consequences ^1,2,6. The synthesis of these materials, encompassing methods from physical vapor deposition to chemical reduction and biological approaches, further introduces variability that can influence their safety profiles ^19,38. Carbon nanotubes, for example, synthesized through various methods, exhibit diverse structural properties that directly correlate with their biological interactions and potential toxicity ²⁹. [Figure 1] illustrates the wide array of nanomaterial types, each presenting unique toxicological considerations.

A central concern, and the focus of this review, is the pervasive issue of underreporting of adverse effects associated with nanomaterials in human health applications. This problem is not unique to nanomedicine; it has been documented in various fields, from drug development to medical device safety ^9,25,26,43. In the context of nanomaterials, several factors contribute to this phenomenon. The novelty of the materials means that long-term effects are inherently unknown, and short-term preclinical studies may not capture subtle, chronic, or latent toxicities ^1,2,6. Furthermore, the complexity of nano-bio interactions makes it challenging to definitively attribute an adverse event to a nanomaterial, particularly when patients have underlying health conditions or are on multiple medications. There is often a strong impetus in early-stage research to highlight efficacy and therapeutic benefits, potentially leading to a de-emphasis or even omission of negative or null toxicity findings, which can be perceived as less “publishable” ⁴³. This publication bias creates a skewed scientific literature that overrepresents positive outcomes and understates potential risks, thus hindering a balanced risk-benefit assessment for regulatory bodies, clinicians, and patients alike. The ethical implications of this underreporting are profound ²¹, demanding a more rigorous, transparent, and comprehensive approach to safety evaluation throughout the entire lifecycle of nanomedicine development, from initial design to clinical translation and post-market surveillance.

Physicochemical Determinants of Nanotoxicity: Bridging Structure and Biological Interaction

The toxicity profile of a nanomaterial is not an intrinsic, fixed property but rather a dynamic outcome of its interaction with biological systems, fundamentally dictated by its physicochemical characteristics. Understanding these determinants is paramount for predicting and mitigating adverse effects, moving beyond empirical observation to mechanism-driven safety design. The initial encounter between a nanomaterial and a biological environment immediately initiates a cascade of interactions that reshape the nanoparticle’s effective identity and subsequent biological fate ²⁰. This phenomenon, often termed the “protein corona effect,” involves the rapid adsorption of biomolecules (primarily proteins, but also lipids, carbohydrates, and nucleic acids) onto the nanoparticle surface upon exposure to biological fluids such as blood plasma ²⁰. The composition and conformation of this protein corona are highly dynamic and influenced by the nanoparticle’s intrinsic properties (size, shape, surface charge, hydrophobicity) and the specific biological milieu ²⁰. The corona effectively acts as the “biological identity” of the nanoparticle, dictating its recognition by cells, biodistribution, cellular uptake mechanisms, and ultimately, its therapeutic efficacy and potential toxicity. Alterations in the corona due to in vivo conditions, such as pH changes or enzymatic activity, can further modify the nanoparticle’s behavior, leading to variable and sometimes unexpected adverse outcomes that are challenging to predict from in vitro studies ²⁰.

Size is arguably the most fundamental determinant of nanotoxicity, as it directly influences how a nanomaterial interacts with cellular machinery and traverses biological barriers. Nanoparticles typically exhibit enhanced cellular uptake compared to larger particles, often through endocytic pathways such as clathrin-mediated endocytosis, caveolae-mediated endocytosis, macropinocytosis, or phagocytosis, depending on their size and surface properties ^1,2,6,20. Particles in the 10-100 nm range are generally optimized for cellular uptake and can also accumulate in specific organs due to the enhanced permeability and retention (EPR) effect in tumor tissues, for instance ^1,2,6. However, smaller nanoparticles (e.g., <10 nm) may exhibit unique properties allowing them to cross typically impermeable biological barriers, such as the blood-brain barrier ³⁹ or placental barrier, leading to systemic distribution and potential off-target toxicity in sensitive organs ^1,2,6,20. The shape of nanomaterials also plays a critical, though often underappreciated, role. Anisotropic shapes, such as nanorods, nanowires, or nanosheets, can exhibit different cellular uptake kinetics, intracellular trafficking, and biodistribution patterns compared to spherical nanoparticles of similar volume ^1,2,6,20. For example, elongated nanoparticles may experience “frustrated phagocytosis” by macrophages, leading to prolonged inflammatory responses, a mechanism analogous to asbestos fibers ^1,2,6. [Figure 2] visually explains these complex interactions.

Surface chemistry and charge are equally crucial in mediating biological interactions and toxicity. The surface charge, typically quantified by zeta potential, dictates colloidal stability in biological fluids and influences interactions with cell membranes, which are negatively charged ^1,2,6,20. Highly positive or negative surface charges can lead to rapid protein adsorption, aggregation, and non-specific cellular uptake, potentially resulting in cytotoxicity or rapid clearance by the reticuloendothelial system ^1,2,6,20. Surface functionalization, a common strategy to engineer nanomaterials for specific biomedical applications, can significantly alter their toxicity profile. For instance, PEGylation (conjugation with polyethylene glycol) is frequently employed to prolong circulation time, reduce protein adsorption, and evade immune surveillance, thereby enhancing biocompatibility ^1,2,6,20. However, even PEGylated nanoparticles are not entirely inert and can still elicit adverse effects, such as accelerated blood clearance upon repeated administration or specific immune responses ⁴⁰. The hydrophobicity or hydrophilicity of the nanoparticle surface further modulates interactions with cell membranes and proteins, impacting cellular internalization and intracellular fate. Hydrophobic nanoparticles tend to accumulate within lipid bilayers and can disrupt membrane integrity, while hydrophilic surfaces generally exhibit lower non-specific binding and better biocompatibility, although this is not universally true ^1,2,6,20.

The intrinsic composition of the nanomaterial core is a primary determinant of its inherent toxicity. Metallic nanoparticles, such as silver (AgNPs) and gold (AuNPs), are widely explored for their antimicrobial, diagnostic, and therapeutic properties ¹⁷. However, AgNPs are well-documented for their cytotoxic effects, often mediated by the release of silver ions (Ag+) that induce oxidative stress, DNA damage, and apoptosis ¹⁷. While AuNPs are generally considered more biocompatible, their long-term fate and potential for accumulation in certain organs remain a concern. Carbon-based nanomaterials, including carbon nanotubes (CNTs) and graphene, possess exceptional mechanical and electrical properties, making them attractive for various biomedical applications ²⁹. Yet, CNTs have been shown to induce pulmonary inflammation, granuloma formation, and fibrosis, particularly for longer, stiffer fibers, echoing the pathogenicity of asbestos ^29,32,48. The purity of carbon nanomaterials is also critical, as residual metallic catalysts from synthesis can significantly contribute to their toxicity ^29,32. Similarly, metal oxide nanoparticles (e.g., TiO2, ZnO) used in sunscreens or as drug delivery vehicles can generate reactive oxygen species and induce cellular damage ^1,2,6. The degradation pathways of nanomaterials in vivo are also crucial but often poorly understood. Biodegradable polymers are designed to break down into non-toxic components, but the kinetics and nature of these degradation products, especially over long periods, are not always fully characterized. Non-degradable or slowly degrading nanomaterials can accumulate in tissues, leading to chronic inflammation or long-term systemic effects ^1,2,6. [Table 1] provides a summary of these critical parameters.

Finally, the aggregation and agglomeration state of nanomaterials in biological media significantly impact their effective size and surface area, thereby altering their biological interactions and toxicity. In vivo, nanoparticles are exposed to complex biological fluids with varying pH, ionic strength, and protein concentrations, which can induce aggregation ^1,2,6,20. Aggregates behave differently from individual nanoparticles, potentially leading to different biodistribution patterns, cellular uptake mechanisms, and ultimately, distinct toxicity profiles. For instance, aggregated nanoparticles might be cleared more rapidly by macrophages, or conversely, might lodge in capillaries, causing microvascular obstruction ^1,2,6,20. The challenge in accurately characterizing nanomaterials in complex biological matrices, both initially and throughout their in vivo journey, presents a significant hurdle in nanotoxicology. Inconsistent characterization methods across studies contribute to discrepancies in reported toxicity data, making it difficult to establish robust structure-activity relationships and ultimately hindering a comprehensive understanding of adverse effects, thereby contributing to their underreporting ²⁴. This highlights the critical need for standardized characterization protocols to ensure reproducibility and comparability of nanotoxicology studies globally.

Systemic and Organ-Specific Manifestations of Nanomaterial Toxicity: Unveiling Hidden Risks

The interaction of nanomaterials with living systems can elicit a broad spectrum of adverse effects, ranging from localized cellular damage to systemic organ dysfunction. These manifestations are often insidious, developing over time, and can be easily overlooked or misattributed, particularly when robust and long-term monitoring protocols are absent. The underlying mechanisms of nanotoxicity are often interconnected, with a few common pathways serving as primary triggers for diverse pathologies across various organ systems. A predominant mechanism is the induction of oxidative stress. Many nanomaterials, regardless of their composition (e.g., metallic, metal oxide, carbon-based), can generate reactive oxygen species (ROS) and reactive nitrogen species (RNS) either directly through their surface chemistry or indirectly by disrupting cellular antioxidant defenses ^1,2,6,32. This imbalance between pro-oxidants and antioxidants leads to oxidative stress, which can damage essential cellular components such as lipids (lipid peroxidation), proteins (protein carbonylation), and DNA (oxidative DNA damage) ^1,2,6,32. Sustained oxidative stress is a known precursor to inflammation, apoptosis, necrosis, and even genotoxicity, serving as a common denominator for many observed adverse effects of nanomaterials ^1,2,6. For example, studies on carbon nanomaterials have extensively linked their toxicity to the generation of ROS and subsequent oxidative damage in various cell types and animal models ³².

Inflammation is another ubiquitous response to nanomaterial exposure, often initiated by oxidative stress or direct interaction with immune cells. Nanomaterials can be recognized as foreign entities by the innate immune system, triggering inflammatory cascades involving the release of pro-inflammatory cytokines (e.g., TNF-α, IL-6, IL-1β) and the recruitment of immune cells like macrophages and neutrophils ^1,2,6,48,49. While acute inflammation is a protective mechanism, chronic or unresolved inflammation can lead to tissue damage, fibrosis, and impaired organ function. This chronic inflammatory state is particularly concerning for nanomaterials designed for long-term residence in the body, as it can contribute to the development of chronic diseases or exacerbate pre-existing conditions ^1,2,6. Furthermore, some nanomaterials have been implicated in genotoxicity, leading to DNA strand breaks, chromosomal aberrations, and micronuclei formation ^1,2,6. This genotoxic potential, often mediated by ROS generation, raises concerns about mutagenicity and carcinogenicity, particularly with long-term or repeated exposures. [Table 2] provides an overview of these general cellular responses.

Beyond these general cellular mechanisms, specific organ systems exhibit particular vulnerabilities to nanomaterial toxicity. The respiratory system is a primary target, especially for airborne nanoparticles or aerosolized nanomedicines. Inhalation of various nanomaterials, including carbon nanotubes, titanium dioxide, and silver nanoparticles, has been shown to induce pulmonary inflammation, alveolar damage, impaired lung function, and even fibrosis in animal models ^{1,2,6,29,32,48}. The morphology of inhaled nanoparticles, particularly the length and rigidity of fibers like carbon nanotubes, significantly influences their pathogenicity, with longer, stiffer fibers posing a greater risk of frustrated phagocytosis and chronic inflammation ^29,32,48. These effects often mimic or exacerbate conditions like asthma and allergic airway disease ⁴⁸, highlighting the need for careful assessment of respiratory exposure pathways, even for nanomaterials not primarily intended for inhalation.

The neurological system represents another critical area of concern. Some nanomaterials, particularly those with small sizes and specific surface chemistries, have demonstrated the ability to cross the blood-brain barrier (BBB), gaining access to the central nervous system ^37,39. Once in the brain, they can induce neuroinflammation, oxidative stress, neuronal damage, and alter neurotransmitter systems ^37,39. Studies have shown that various nanoparticles can accumulate in different brain regions, potentially leading to long-term neurocognitive deficits or exacerbating neurodegenerative diseases ^37,39. The long-term implications of such accumulation are profoundly understudied, and subtle neurological impairments could easily be overlooked in standard toxicity assays, contributing significantly to underreporting. [Figure 3] illustrates these mechanisms.

The hepatic (liver) and renal (kidney) systems are crucial for metabolism, detoxification, and excretion, making them susceptible to nanomaterial accumulation and toxicity. Nanomaterials are often cleared from the bloodstream by the liver (e.g., Kupffer cells) and excreted via the kidneys. High doses or chronic exposure can lead to hepatotoxicity (e.g., inflammation, steatosis, necrosis) and nephrotoxicity (e.g., tubular damage, impaired glomerular filtration) ^1,2,6. These effects can disrupt the body’s homeostatic balance and impair the clearance of other substances, creating a vicious cycle of toxicity. The gastrointestinal tract is another important route of exposure, particularly for nanomaterials in food applications ¹³ or orally administered nanomedicines. While the gut barrier can limit absorption, some nanomaterials can traverse this barrier, leading to systemic exposure or localized effects on the gut microbiome and intestinal epithelium ¹³.

Emerging evidence also points to potential adverse effects on the reproductive system and embryonic development, areas that are often neglected in initial safety assessments. Certain nanomaterials have been shown to cross the placental barrier, potentially affecting fetal development, or to accumulate in reproductive organs, raising concerns about fertility and transgenerational effects ^1,2. The cardiovascular system is also not immune; nanomaterials can induce endothelial dysfunction, promote thrombosis, or exacerbate atherosclerosis, often as secondary effects of systemic inflammation or oxidative stress ^1,2. The complexity of these systemic and organ-specific interactions, coupled with the potential for chronic and latent effects, makes comprehensive safety assessment challenging. Many adverse effects may not manifest acutely but rather accumulate over time, leading to delayed onset pathologies. This delayed manifestation, combined with the difficulty in establishing clear causal links in heterogeneous biological systems, significantly contributes to the underreporting of adverse effects of nanomaterials in human health applications. The ethical imperative to fully characterize these risks before widespread clinical adoption is undeniable.

Immunomodulation and Chronic Inflammation: A Latent Threat

The immune system, a highly sophisticated network designed to distinguish self from non-self, represents a primary and exquisitely sensitive target for nanomaterial interactions. The unique physicochemical properties of nanomaterials, particularly their size, surface chemistry, and charge, dictate how they are recognized by immune cells and subsequently processed, often triggering complex and varied immune responses ^40,48,49. These interactions can range from acute inflammatory reactions to subtle, chronic immunomodulation, with profound implications for long-term health and the safety of nanomedicines. The immune system’s recognition of nanomaterials is often multifaceted, involving both direct interactions with immune cell receptors and indirect interactions mediated by the protein corona ^20,40,49. Upon entering a biological environment, nanomaterials are rapidly coated with plasma proteins, forming the aforementioned protein corona, which then dictates how immune cells perceive and interact with the nanoparticle ²⁰. Variations in the protein corona composition can lead to different immune cell activation profiles, making the prediction of immunotoxicological outcomes challenging ²⁰. For instance, a protein corona rich in complement proteins might trigger complement activation, leading to inflammation and rapid clearance, while a corona rich in specific opsonins might facilitate uptake by phagocytic cells ^20,40.

Acute inflammatory responses are a common initial reaction to nanomaterial exposure. Macrophages, the sentinel cells of the innate immune system, are often the first responders, attempting to engulf and clear nanoparticles ^40,49. This phagocytosis can lead to the activation of intracellular signaling pathways, including the inflammasome, resulting in the release of pro-inflammatory cytokines such as IL-1β and IL-18 ^40,49. While acute inflammation is a protective mechanism, prolonged or excessive activation of these pathways can contribute to tissue damage. For example, carbon nanotubes and other insoluble nanoparticles can induce persistent inflammation, leading to granuloma formation and fibrosis, similar to the pathology observed with asbestos fibers ^29,32,48. [Figure 4] provides a detailed illustration of these cellular interactions.

Beyond acute inflammation, nanomaterials pose a latent threat through their capacity for chronic immunomodulation. This encompasses a spectrum of effects, from immunosuppression to immunostimulation, and even the induction of autoimmune-like responses. Some nanomaterials can impair the function of immune cells, reducing their ability to respond to pathogens or eliminate cancerous cells, thereby potentially increasing susceptibility to infections or tumor progression. Conversely, others can act as adjuvants, enhancing immune responses. While this property is exploited in vaccine development, uncontrolled immunostimulation can lead to hypersensitivity reactions or exacerbate autoimmune conditions ^40,48. For instance, certain nanoparticles have been shown to exacerbate allergic airway disease and asthma by acting as irritants or adjuvants, amplifying the inflammatory response in the lungs ⁴⁸. The precise mechanisms by which nanomaterials modulate adaptive immunity, affecting T-cell and B-cell responses, are still being elucidated, but they represent a critical area for investigation, particularly for nanomaterials intended for repeated administration or long-term systemic presence. The development of new or exacerbated allergies, such as atopic dermatitis ⁵¹, due to nanomaterial exposure is a significant concern that often goes underreported due to its delayed onset and complex etiology.

The impact of nanomaterials on innate immune activation by live bacteria is also a crucial aspect of immunomodulation. Studies have shown that nanoparticles can interact with bacterial components and immune cells, influencing the host’s response to infection ⁴⁹. This complex interplay can either enhance or diminish the immune system’s ability to combat pathogens, depending on the nanomaterial’s properties and the specific bacterial strain ⁴⁹. Such interactions highlight the need for careful consideration of nanomedicine safety in immunocompromised individuals or in the context of concurrent infections. The subtle and chronic nature of these immunomodulatory effects makes them particularly challenging to detect and quantify in standard preclinical toxicology studies. Many in vitro assays are limited in their ability to mimic the complexity of the in vivo immune system, which involves multiple cell types, soluble mediators, and intricate feedback loops. Animal models, while more comprehensive, may not fully recapitulate human immune responses due to species-specific differences ⁴⁰. This methodological gap contributes significantly to the underreporting of immunotoxicological effects, as these subtle changes may not result in overt clinical signs in short-term studies but could have profound long-term consequences. The absence of standardized, comprehensive immunotoxicity testing protocols for nanomaterials further exacerbates this issue, leading to inconsistencies in data and hindering cross-study comparisons. [Table 3] illustrates the range of parameters that should ideally be evaluated.

Moreover, the concept of “frustrated phagocytosis” is particularly relevant for insoluble, high-aspect-ratio nanomaterials like long carbon nanotubes. When immune cells, such as macrophages, attempt to engulf these materials but cannot fully internalize them, they can enter a state of chronic activation, continuously releasing pro-inflammatory mediators ^29,32,48. This persistent inflammatory signaling can lead to sustained tissue damage, fibrosis, and potentially contribute to carcinogenesis over prolonged exposure periods. The long-term fate of nanomaterials within immune cells, whether they are degraded, exocytosed, or remain sequestered, also influences the duration and nature of the immune response. Non-degradable nanomaterials that persist within macrophages can lead to chronic low-grade inflammation, contributing to systemic effects that are difficult to link directly to the initial exposure ^1,2. The ethical implications of introducing materials with such complex and potentially chronic immunomodulatory effects into the human body necessitate a profound shift towards more rigorous and prolonged immunotoxicity assessments. Without a thorough understanding of these latent immune threats, the promise of nanomedicine risks being undermined by unforeseen and underreported adverse effects that could manifest years after initial exposure, especially in vulnerable populations such as children ²⁶ or individuals with compromised immune systems.

Methodological Gaps and Ethical Imperatives in Nanotoxicology Reporting

The systematic underreporting of adverse effects of nanomaterials in human health applications stems not only from inherent scientific complexities but also from pervasive methodological gaps in current nanotoxicology assessments and, crucially, from a lack of stringent ethical and regulatory imperatives for transparent disclosure. The journey from bench to bedside for a nanomedicine is fraught with challenges, and at each stage, potential adverse effects can be missed, misinterpreted, or simply not reported, creating a significant knowledge gap that hinders informed decision-making. A primary limitation lies in the predictive power of current preclinical models. While in vitro cell culture systems offer a controlled environment for studying cellular responses to nanomaterials, their inherent simplicity often fails to recapitulate the intricate complexity of in vivo biological systems ^1,2,6,20. Two-dimensional cell cultures lack the physiological architecture, cellular heterogeneity, dynamic fluid flow, and complex immune interactions present in living organisms. Advanced in vitro models, such as 3D organoids, spheroids, and organ-on-a-chip systems, offer promising avenues to bridge this gap by mimicking tissue-level organization and physiological microenvironments ⁵³. However, even these sophisticated models are still under development and validation, and their ability to fully predict systemic human responses remains to be definitively established. For instance, while an in vitro model might show a dose-dependent cytotoxicity, it cannot account for biodistribution, metabolism, or the compensatory mechanisms of a whole organism.

Animal models, while essential for in vivo assessment, also possess significant limitations in fully predicting human toxicity. Species-specific differences in anatomy, physiology, metabolism, and immune responses can lead to discrepancies between animal and human reactions to nanomaterials ^1,2,6,20. For example, the toxicokinetics and toxicodynamics of a particular nanomaterial might vary significantly between rodents and humans, making direct extrapolation challenging. The choice of animal model, exposure route (e.g., intravenous, oral, inhalation), and dose regimen also critically influence experimental outcomes, and these parameters are not always optimized to reflect realistic human exposure scenarios ⁴¹. Furthermore, a pervasive oversight in preclinical research, not unique to nanotoxicology but particularly critical given the novelty and complexity of nanomaterials, is the inadequate consideration of sex as a biological variable ^52,55. Hormonal differences, metabolic rates, immune system variations, and genetic factors between sexes can lead to differential susceptibility to adverse effects and distinct toxicological profiles ^52,55. Neglecting sex-specific investigations in preclinical studies can result in underreported adverse effects in one sex, leading to incomplete safety assessments and potentially endangering specific patient populations. [Figure 5] highlights this critical gap.

Challenges in exposure assessment and biomonitoring further compound the problem of underreporting. Accurately detecting and quantifying nanomaterials and their degradation products in complex biological matrices (e.g., blood, urine, tissues, wastewater ⁵⁰) at physiologically relevant concentrations is technically demanding ^35,41. The small size and often low concentrations of nanomaterials make them difficult to distinguish from endogenous biological components or environmental contaminants. This analytical challenge hinders precise dose-response correlations and makes it difficult to track the long-term fate, persistence, and bioaccumulation of nanomaterials in vivo ^1,2,6. Without robust methods for biomonitoring, subtle accumulation or chronic, low-level toxicity can easily go unnoticed, contributing to the underreporting of latent adverse effects ³⁵. The issue extends to the lack of standardized, validated characterization techniques for nanomaterials in situ within biological samples, which is crucial for understanding how their properties evolve over time in the body ²⁴.

The problem of underreporting is multifaceted and extends beyond purely technical limitations. Publication bias is a well-recognized phenomenon in scientific research, where studies reporting positive or statistically significant findings are more likely to be published than those reporting negative or null results ⁴³. In the context of nanomedicine, this translates into a tendency to publish successful therapeutic applications while downplaying or omitting studies that reveal toxicity or lack of efficacy ^9,25,26. This creates an artificially positive landscape of nanomedicine, masking potential risks and hindering a balanced scientific discourse. Commercial pressures also play a significant role; the immense investment in developing novel nanomedicines can create an environment where the focus shifts heavily towards demonstrating efficacy for market approval, potentially at the expense of comprehensive adverse effect investigation ³⁴. This can lead to selective reporting or the design of studies that are less likely to uncover subtle toxicities.

Moreover, the absence of standardized protocols for nanotoxicology research makes it difficult to compare results across different studies and laboratories ^1,2,6. Variations in nanomaterial synthesis ¹⁹, characterization ²⁴, experimental design (e.g., cell lines, animal strains, dosing regimens), and endpoint measurements contribute to inconsistencies and make it challenging to establish robust safety guidelines. This lack of harmonization can allow adverse effects to be missed or dismissed due to methodological variability. The complexity of data interpretation is another factor; attributing an adverse event directly to a nanomaterial can be challenging, especially in clinical settings where patients may have multiple comorbidities or be on polypharmacy. Subtle symptoms might be dismissed as unrelated or attributed to other factors, particularly if the adverse effect is not well-established for the specific nanomaterial. [Table 4] provides a summary of these issues.

Addressing these methodological gaps and combating underreporting necessitates a strong ethical and regulatory imperative. The principle of “responsible innovation” must guide nanomedicine development, integrating safety considerations from the earliest stages of design (“Safe-by-Design” principles) ²¹. This proactive approach prioritizes the synthesis of inherently less toxic nanomaterials and the development of robust, predictive safety assessments. There is an urgent need for greater transparency and mandatory data sharing of all toxicity findings, both positive and negative, through public registries and open-access platforms. This would help counteract publication bias and provide a more complete picture of the nanomaterial’s safety profile. Regulatory bodies worldwide need to develop and enforce harmonized, comprehensive guidelines for nanomaterial safety assessment, including requirements for long-term studies, sex-specific analyses, and advanced biomonitoring techniques. For clinical trials, the informed consent process must transparently communicate the full spectrum of known and potential adverse effects, acknowledging the inherent uncertainties associated with novel nanomaterials. Ultimately, moving beyond the promise to a truly informed and responsible nanomedicine frontier requires a collective commitment from researchers, industry, regulators, and funding agencies to prioritize safety, transparency, and ethical conduct above all else.

Critical Evaluation and Future Directions: Navigating the Nanomedicine Frontier Responsibly

The journey of nanomaterials from promising scientific curiosities to indispensable tools in human health applications is marked by both exhilarating breakthroughs and profound challenges. This review has critically examined the often-underreported adverse effects of nanomaterials, arguing that a comprehensive understanding of their true risk-benefit profile remains elusive due to a confluence of scientific complexities, methodological limitations, and systemic underreporting. The central insight is that the unique physicochemical properties of nanomaterials—size, shape, surface chemistry, and composition—are not merely determinants of their therapeutic efficacy but are equally, if not more, critical in dictating their intricate and often unpredictable interactions with biological systems, leading to a spectrum of adverse outcomes ^1,2,6,20. These interactions initiate common cellular responses such as oxidative stress, inflammation, and genotoxicity, which then cascade into organ-specific pathologies affecting the respiratory, neurological, immune, hepatic, and renal systems ^{1,2,6,32,39,40,48}. The insidious nature of immunomodulation and chronic inflammation, often latent and difficult to detect, represents a particularly significant and underappreciated threat, potentially leading to long-term health consequences like allergies, autoimmunity, or impaired immune surveillance ^40,48,49.

Despite significant advancements, several critical controversies and unresolved gaps persist, demanding urgent attention. The predictive power of current in vitro and in vivo models for human toxicity remains a major challenge. While new technologies like organ-on-a-chip systems offer improved physiological relevance, their ability to fully recapitulate the complexity of human systemic responses and long-term effects is still under validation. A fundamental gap lies in understanding the long-term fate, degradation pathways, and bioaccumulation of diverse nanomaterials in vivo. Many studies are limited to acute or sub-acute exposures, failing to capture chronic toxicities that may manifest years after initial exposure. The precise mechanisms governing the transition from acute inflammation to chronic immunomodulation and the development of latent adverse effects are not fully elucidated for many nanomaterial classes. Furthermore, the variability introduced by the protein corona effect, which dynamically reshapes the nanoparticle’s biological identity, means that in vitro characterization alone is insufficient, and in situ characterization in biological fluids remains a formidable analytical challenge ^20,24. The pervasive issue of underreporting, driven by publication bias, commercial pressures, and a lack of standardized, sensitive detection methods, continues to obscure the true safety landscape of nanomedicines, creating an ethical dilemma that undermines informed decision-making by stakeholders ^{9,21,25,26,43}.

Navigating the nanomedicine frontier responsibly requires a concerted, multidisciplinary effort focused on mitigating these risks and ensuring transparency. Future directions must prioritize the development and widespread adoption of robust, standardized characterization techniques for nanomaterials, not only in their pristine state but crucially within complex biological matrices and throughout their in vivo journey ²⁴. This will enable a more accurate correlation between physicochemical properties and biological outcomes. Simultaneously, there is an urgent need for next-generation toxicology models that are more predictive of human responses. This includes further developing and validating advanced 3D in vitro models, leveraging computational toxicology, and designing animal studies that are more translatable to human physiology, including a mandatory and rigorous assessment of sex as a biological variable ^52,55. Such studies must move beyond short-term observations to embrace longitudinal designs that can uncover chronic and latent adverse effects, including subtle immunomodulation and neurotoxicity ^37,39,40.

To directly address the systemic underreporting of adverse effects, a paradigm shift in scientific publishing and regulatory oversight is essential. This includes promoting open science initiatives, mandating the registration of all preclinical and clinical studies, and requiring the public disclosure of all toxicity data, including negative or null findings, through centralized, accessible databases. Such transparency is critical for combating publication bias and fostering a more complete and accurate understanding of nanomaterial safety. Regulatory bodies must harmonize guidelines for nanomaterial safety assessment globally, ensuring consistency in testing protocols, endpoints, and reporting requirements. This harmonization should encompass specific guidelines for assessing immunotoxicity, genotoxicity, neurotoxicity, and reproductive toxicity, areas where current assessments are often insufficient. Furthermore, the integration of “Safe-by-Design” principles from the earliest stages of nanomaterial development is paramount ²¹. This proactive approach prioritizes the synthesis of nanomaterials with optimized safety profiles, reducing potential adverse effects at the source, rather than attempting to mitigate them retrospectively. [Table 5] outlines these critical steps.

In conclusion, the promise of nanomaterials in human health applications is immense and continues to inspire groundbreaking innovations. However, to truly unlock this potential, the scientific community, industry, and regulatory bodies must collectively confront the challenge of underreported adverse effects with unwavering commitment and transparency. Moving “beyond the promise” necessitates a rigorous, ethical, and proactive approach to safety assessment, one that prioritizes a comprehensive understanding of nano-bio interactions, invests in advanced toxicological methodologies, and ensures the open and honest reporting of all findings. Only by embracing this holistic perspective can we responsibly navigate the nanomedicine frontier, safeguarding human health while harnessing the transformative power of nanotechnology for the betterment of society.